Menu
No results found.
Weekly Share Price & Valuation Overview
West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- ROE ≥15% reflects strong returns on shareholder equity.
- ROA ≥7% shows efficient use of assets.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Market Cap Total equity value of the company (share price × shares outstanding).
- USD 17.70B
- Enterprise Value Operating value: market cap + total debt − cash.
- USD 17.50B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- USD 2.96B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- USD 1.04B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- USD 789.50M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- USD 40.83
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 6.67
- Shares Outstanding
- 71.91M
- Float Shares
- 71.39M
- Implied Shares Outstanding
- 71.91M
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
20.87%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
26.67%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
35.27%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
16.48%
- ROA Strong Return on assets: net income ÷ total assets.
-
10.53%
- ROE Excellent Return on equity: net income ÷ shareholder equity.
-
17.72%
- Revenue Growth Year-over-year revenue growth.
-
9.20%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
20.50%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
18.40%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.85
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.11
- Total Cash Cash and equivalents.
- USD 509.70M
- Total Debt Short + long-term interest-bearing debt.
- USD 308.20M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- USD -201.50M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 0.39
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- USD 676.70M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- USD 207.85M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
22.86%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
7.02%
- Cash Conversion (OpCF/EBITDA)
- 0.86
- Dividend Yield suppressed due to an anomalous value from the feed (>30%).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.